- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 |
| clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05071846 | MVX-ONCO-2 in Advanced Solid Tumors | active not recruiting | Phase 1 | 6 | University Hospital, GenevaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05752552 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | recruiting | Phase 1 | 55 | DeuterOncologyINDUSTRY | 3 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05223608 | Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy(ImmuCCo) | recruiting | N/A | 651 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT00477958 | Assessment Tool for Older Patients With Cancer | active not recruiting | N/A | 1,062 | City of Hope Medical CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00900471 | Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors | recruiting | — | 20,000 | Wake Forest University Health SciencesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT00571389 | A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. | recruiting | — | 1,500 | BioCytics, Inc.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04143711 | Study of DF1001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 270 | Dragonfly TherapeuticsINDUSTRY | 6 | Mar 18, 2026 | clinicaltrials |
| NCT04443088 | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors(KEYNOTE-E12) | recruiting | Phase 1 | 78 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 87 | AkesoINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06108479 | Study of DF6215 in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Dragonfly TherapeuticsINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00343460 | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 1,428 | Heron TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07137195 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05381909 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | terminated | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Feb 20, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT04932525 | Gustave Roussy Cancer Profiling(STING) | recruiting | N/A | 20,000 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06772090 | Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies | not yet recruiting | N/A | 40 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06397963 | Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours | recruiting | N/A | 18 | Grit BiotechnologyINDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | completed | Phase 2 | 16 | CytoDyn, Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07153094 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT07152353 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02215928 | Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | terminated | Phase 1 | 67 | Debiopharm International SAINDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2026source: clinicaltrials